Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance
See more from Benzinga
Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters
South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.